Systemic lupus erythematosus

Gatto M et al. Nat Rev Rheum 2018. doi: 10.1038/s41584-018-0133-2

Keeling SO et al. J Rheumatol 2018. doi: 10.3899/jrheum.171459

Keeling SO et al. J Rheumatol 2018. doi: 10.3899/jrheum.171307

Hou C, Jin O, Zhang X. Clin Rheumatol 2018. doi: 10.1007/s10067-018-4198-8

Dai ZW et al. Clin Rheumatol 2018. doi: 10.1007/s10067-018-4189-9

Di Matteo A et al. Rheumatology (Oxford) 2018. doi: 10.1093/rheumatology/key189

Tekin et al. report the case of a previously healthy 16-year-old girl with an acquired angioedema as a rare and initial presentation of systemic lupus erythematosus, and review the related literature.

Tekin ZE, Yener GO, Yüksel S. Rheumatol Int 2018. doi: 10.1007/s00296-018-4088-z

Ceccarelli F et al. Arthritis Res Ther 2018; 20: 126. doi: 10.1186/s13075-018-1622-z

Katz-Talmor D et al. Nat Rev Rheumatol 2018. doi: 10.1038/s41584-018-0025-5

Zhou H et al. Clin Rheumatol 2018. doi: 10.1007/s10067-018-4124-0

Erre GL et al. Rheumatol Int 2018; Advance online publication. doi: 10.1007/s00296-018-4039-8

Mavrogeni SI et al. Rheumatol Int 2018; Advance online publication. doi: 10.1007/s00296-018-4004-6

Barturen G et al. Nat Rev Rheumatol 2018; 14: 75–93. doi: 10.1038/nrrheum.2017.220

The role of anti-inflammatory cytokines interleukin (IL) 10 and IL-37 in systemic lupus erythematosus is under debate. Godsell et al investigate their role in the disease as well as their potential as biomarkers. 

Scientific Reports 2016;6:34604. doi:10.1038/srep34604

This chapter provide a critical overview on systemic lupus erythematosus clinical manifestations according to their severity and discusses new insights on classification criteria for this condition.

Sciascia S & Cuadrado MJ. In: Connective Tissue Disease. Edited by Roccatello D & Emmi L. Springer International Publishing Switzerland, 2016. doi:10.1007/978-3-319-24535-5_4

Cutaneous involvement is common in systemic lupus erythematosus (SLE). This chapter provides insights into the cutaneous features associated with SLE, with emphasis on classification, diagnostic, and treatment aspects.

Ribero S, Lipsker D, & Borradori L. In: Connective Tissue Disease. Edited by Roccatello D & Emmi L. Springer International Publishing Switzerland, 2016. doi:10.1007/978-3-319-24535-5_7

Autoantibodies are normally present several years prior to systemic lupus erythematosus manifestations. This chapter reviews the autoantibodies most commonly used as diagnostic biomarkers in clinical practice.

Sciascia S & Bertolaccini ML. In: Connective Tissue Disease. Edited by Roccatello D & Emmi L. Springer International Publishing Switzerland, 2016. doi:10.1007/978-3-319-24535-5_5

Baglivo and Ribi summarize the etiology and pathophysiology of systemic lupus erythematosus with a focus on clinical manifestations (particularly ocular), diagnosis, therapy, and prognosis.

Baglivo E & Ribi C. In: Intraocular inflammation. Edited by Zierhut M et al. Springer-Verlag Berlin Heidelberg, 2016. doi:10.1007/978-3-540-75387-2_68

Antibodies that recognize and bind to DNA are in regular use as biomarkers for diagnosis of systemic lupus erythematosus. This review highlights current and future challenges of such biomarkers. 

Nat Rev Rheumatol 2016;12:102–110. doi:10.1038/nrrheum.2015.151